Voyager Therapeutics (NASDAQ:VYGR) Cut to “Hold” at StockNews.com

Voyager Therapeutics (NASDAQ:VYGR) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Sunday.

Several other research firms have also recently weighed in on VYGR. Leerink Partners began coverage on shares of Voyager Therapeutics in a research report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Voyager Therapeutics in a report on Thursday, October 24th. Wedbush reduced their price target on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. Finally, Leerink Partnrs upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, October 16th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Voyager Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $17.43.

Voyager Therapeutics Stock Up 0.4 %

VYGR opened at $7.13 on Friday. Voyager Therapeutics has a twelve month low of $5.71 and a twelve month high of $11.72. The company has a fifty day moving average of $6.60 and a 200-day moving average of $7.54. The stock has a market cap of $388.82 million, a PE ratio of 25.46 and a beta of 0.89.

Insider Transactions at Voyager Therapeutics

In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the company’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total transaction of $34,914.18. Following the completion of the sale, the insider now directly owns 86,001 shares in the company, valued at $500,525.82. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 4.53% of the company’s stock.

Institutional Trading of Voyager Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of VYGR. BNP Paribas Financial Markets grew its position in shares of Voyager Therapeutics by 198.6% in the 1st quarter. BNP Paribas Financial Markets now owns 48,769 shares of the company’s stock worth $454,000 after buying an additional 32,437 shares during the period. Empowered Funds LLC lifted its stake in Voyager Therapeutics by 8.2% during the 1st quarter. Empowered Funds LLC now owns 39,471 shares of the company’s stock valued at $367,000 after acquiring an additional 2,975 shares during the period. ProShare Advisors LLC bought a new position in Voyager Therapeutics during the 1st quarter valued at about $101,000. Vanguard Group Inc. lifted its stake in shares of Voyager Therapeutics by 27.8% in the 1st quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock worth $30,087,000 after purchasing an additional 702,030 shares during the period. Finally, Acadian Asset Management LLC lifted its stake in shares of Voyager Therapeutics by 10.1% in the 1st quarter. Acadian Asset Management LLC now owns 459,850 shares of the company’s stock worth $4,280,000 after purchasing an additional 42,029 shares during the period. 48.03% of the stock is owned by hedge funds and other institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.